DCC hosts BioMelbourne Network Initiatives
Wednesday, 31 August 2011
DCC continued its support of BioMelbourne Network initiatives by again hosting a lunch in the CEO luncheon forum series on Wednesday, 31 August, 2011. This series has been a great success in facilitating networking between members of Australia’s life science community. Dr Peter Smith, the CEO of Alchemia Pty Ltd, used his company’s experiences in developing the drug, Fondaprinux, including the registration process before the FDA and its commercialisation through a large pharmaceutical company, to outline the challenges which face industry in the pharmaceutical development path.
It was an illuminating talk and stimulated lively discussion amongst the 28 guests. The ensuing discussion highlighted the importance of a strategic approach to pharmaceutical development in Australia. The importance of this series is evidenced by the recent sponsorship arrangement with Commonwealth Department of Innovation, Industry, Science and Research, and DCC was pleased to be the host sponsor for the lunch. Dr Mathew Lucas, Dr John Hughes and Dr Alex Tzanidis from DCC were in attendance with Mat formally welcoming the guests and introducing Dr Smith.
L-R Dr Peter Smith, Dr Mathew Lucas, Michelle Gallaher and Dr John Hughes.